Joe Rogan Experience #2534 - Annie Jacobsen · Aired Jul 31, 2026
Claim summary · not a verbatim quotation
The use of Vitamin D, K2, and magnesium would have significantly lowered the COVID-19 death rate.
The finding
What the evidence shows
There's a kernel of real science here, but not enough to support 'significantly lowered.' Vitamin D deficiency has been linked to worse COVID-19 outcomes in observational studies, and some supplementation trials point to modest benefits like fewer ICU transfers, but the NIH says there's still insufficient evidence to recommend vitamin D specifically for treating or preventing COVID-19, and no clinical trials establish a death rate benefit from combining it with K2 and magnesium.
Read the supporting source · en.wikipedia.org ↗Quick answer & review status
Quick answer
Is it true that the use of Vitamin D, K2, and magnesium would have significantly lowered the COVID-19 death rate?
Partly. The claim stretches what the evidence shows. There's a kernel of real science here, but not enough to support 'significantly lowered.' Vitamin D deficiency has been linked to worse COVID-19 outcomes in observational studies, and some supplementation trials point to modest benefits like fewer ICU transfers, but the NIH says there's still insufficient evidence to r. Joe Rogan said it (matched by voice) on Joe Rogan Experience #2534 - Annie Jacobsen, aired Jul 31, 2026, at 1:38:09. The supporting source is en.wikipedia.org, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.